SOPHiA GENETICS
SOPH · NASDAQ · Healthcare
$8.19
$0.33 (-3.99%) today
Market Cap
$697.20M
24h Volume
$7.9M
P/E Ratio
0.0
52w High
$8.92
52w Low
$3.32
Est. AI Revenue
90%
7-Day Sparkline (Static)
Company facts
Performance
About SOPHiA GENETICS
SOPHiA GENETICS sells AI analysis for clinical genomics. Hospitals and laboratories run patient samples on their own sequencers, then send the data to the cloud based SOPHiA DDM platform, which applies algorithms to identify disease causing variants in cancer and rare disorders. The company earns recurring revenue per analysis.
SOPHiA DDM supports applications across solid tumors, blood cancers, hereditary disorders, and multimodal analysis that combines genomic, imaging, and clinical data. Its decentralized model contrasts with centralized labs because the AI travels to the data rather than samples traveling to one facility.
Founded in 2011 and headquartered in Rolle, Switzerland, SOPHiA GENETICS employs about 400 people and trades on the NASDAQ, serving a network of more than 750 hospitals and laboratories worldwide.
SOPHiA GENETICS in the AI buildout
SOPHiA GENETICS sits in the AI Healthcare layer and the AI Applications layer: its product is analysis software sold as a recurring, per use service. Nearly all revenue flows through the DDM platform, so the company's fortunes track adoption of data driven medicine in hospitals rather than AI infrastructure spending. The decentralized model gives it a broad institutional network whose accumulated data strengthens its algorithms, while reimbursement pressure on genomic testing and its small scale remain the main constraints.
SOPH is tracked in AI Healthcare and AI Applications, rated Core on the AI Exposure leaderboard.
By the numbers
52-week range
SOPH trades at $8.19, 87% of the way up its 52-week range of $3.32 to $8.92.
Market cap
Market capitalization is $697.20M, with an AI Exposure Score of 85 out of 100.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does SOPHiA GENETICS do?
SOPHiA GENETICS provides a cloud platform that analyzes genomic and clinical data for hospitals and laboratories. Institutions sequence patient samples locally and use SOPHiA DDM to detect and interpret variants in cancer and rare diseases, paying the company per analysis.
How is SOPHiA GENETICS exposed to AI?
Nearly all revenue comes from AI powered analysis on the DDM platform; the algorithms are the product being sold. Supercycle rates it Core with an AI Exposure Score of 85 out of 100, near the top of the Core tier.
What is SOPHiA DDM?
SOPHiA DDM is the company's cloud platform for data driven medicine. It ingests sequencing output and other clinical data, applies AI to detect variants and patterns, and returns structured reports clinicians use for diagnosis and treatment decisions across oncology and rare disease.
Is SOPH a pure play AI stock?
Close. The company exists to sell AI analysis and has no meaningful non-AI business, but Supercycle rates it Core at 85 rather than Pure Play, reflecting its dependence on hospital genomics adoption and its small commercial scale.
Who leads SOPHiA GENETICS?
Ross Muken serves as chief executive, having previously been the company's president and chief financial and operating officer. SOPHiA GENETICS was co-founded in 2011 by Jurgi Camblong, who led it from founding through its public listing.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.